TPA
BMY icon

Trivium Point Advisory’s Bristol-Myers Squibb BMY Stock Holding History

Trivium Point Advisory’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$479K Sell
7,891
-2,885
-27% -$168K 0.09% 195
2025
Q4 		$581K Buy
10,776
+2,212
+26% +$106K 0.06% 228
2025
Q3 		$386K Sell
8,564
-2,509
-23% -$117K 0.04% 266
2025
Q2 		$513K Sell
11,073
-208
-2% -$10.2K 0.06% 235
2025
Q1 		$688K Buy
11,281
+1,489
+15% +$86.8K 0.09% 200
2024
Q4 		$554K Buy
9,792
+1,899
+24% +$106K 0.07% 214
2024
Q3 		$461K Buy
7,893
+620
+9% +$29.1K 0.06% 228
2024
Q2 		$302K Buy
7,273
+1,124
+18% +$50.3K 0.05% 248
2024
Q1 		$333K Buy
6,149
+1,493
+32% +$76.1K 0.07% 185
2023
Q4 		$239K Sell
4,656
-257
-5% -$13.5K 0.06% 182
2023
Q3 		$281K Sell
4,913
-38
-0.8% -$2.33K 0.08% 165
2023
Q2 		$317K Sell
4,951
-279
-5% -$18.7K 0.09% 165
2023
Q1 		$362K Sell
5,230
-38
-0.7% -$2.68K 0.1% 160
2022
Q4 		$385K Sell
5,268
-38
-0.7% -$2.87K 0.11% 153
2022
Q3 		$373K Sell
5,306
-276
-5% -$20K 0.12% 154
2022
Q2 		$419K Sell
5,582
-1,837
-25% -$140K 0.13% 154
2022
Q1 		$559K Sell
7,419
-499
-6% -$33.5K 0.12% 162
2021
Q4 		$494K Buy
7,918
+917
+13% +$53.8K 0.1% 165
2021
Q3 		$413K Sell
7,001
-16,832
-71% -$1.11M 0.1% 165
2021
Q2 		$1.59M Sell
23,833
-2,513
-10% -$164K 0.4% 88
2021
Q1 		$1.66M Sell
26,346
-2,735
-9% -$170K 0.45% 82
2020
Q4 		$1.81M Sell
29,081
-1,527
-5% -$93.9K 0.52% 60
2020
Q3 		$1.84M Sell
30,608
-1,047
-3% -$63K 0.65% 49
2020
Q2 		$1.91M Buy
31,655
+24,179
+323% +$1.45M 0.75% 40
2020
Q1 		$435K Buy
7,476
+3,740
+100% +$229K 0.22% 105
2019
Q4 		$240K Sell
3,736
-1,049
-22% -$60.1K 0.09% 148
2019
Q3 		$243K Buy
4,785
+339
+8% +$15.9K 0.11% 140
2019
Q2 		$202K Sell
4,446
-376
-8% -$17.5K 0.09% 159
2019
Q1 		$230K Buy
4,822
+810
+20% +$40.3K 0.11% 146
2018
Q4 		$209K Buy
+4,012
New +$216K 0.13% 131

Other funds holding BMY

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Trivium Point Advisory's BMY Position: Q1 2026 in Review

Trivium Point Advisory reduced its Bristol-Myers Squibb (BMY) stake by 27% in Q1 2026, selling an estimated $168K and leaving 7,891 shares worth $479K. The position accounts for 0.09% of the portfolio, ranked #195.

Trivium Point Advisory first reported a position in BMY in Q4 2018 and has held it in 30 quarters since. The position peaked at $1.91M in Q2 2020. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Trivium Point Advisory held 7,891 shares of Bristol-Myers Squibb worth $479K as of Q1 2026.
  • Trivium Point Advisory sold 2,885 Bristol-Myers Squibb shares in Q1 2026, an estimated $168K.
  • Bristol-Myers Squibb made up 0.09% of Trivium Point Advisory's portfolio in Q1 2026, its #195 holding.
  • Trivium Point Advisory first reported a position in Bristol-Myers Squibb in Q4 2018 and has held it in 30 quarters since.
  • Trivium Point Advisory's Bristol-Myers Squibb position peaked at $1.91M in Q2 2020.
  • 2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Trivium Point Advisory's 13F filing for Q1 2026, filed 21 Apr 2026.